

Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/S21F80D10309EN.html>

Date: September 2022

Pages: 91

Price: US\$ 2,000.00 (Single User License)

ID: S21F80D10309EN

Abstracts

Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinocerebellar Ataxia (SCA) - Drugs In Development, 2022, provides an overview of the Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline landscape.

Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Symptoms include poor coordination, unsteady walk and a tendency to stumble, change in speech and difficulty swallowing.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinocerebellar Ataxia (SCA) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide also reviews of

Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players,...

key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4, 13 and 8 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 4 and 2 molecules, respectively.

Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (SCA) (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Spinocerebellar Ataxia (SCA) - Overview

Spinocerebellar Ataxia (SCA) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Spinocerebellar Ataxia (SCA) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Spinocerebellar Ataxia (SCA) - Companies Involved in Therapeutics Development

Spinocerebellar Ataxia (SCA) - Drug Profiles

Spinocerebellar Ataxia (SCA) - Dormant Projects

Spinocerebellar Ataxia (SCA) - Discontinued Products

Spinocerebellar Ataxia (SCA) - Product Development Milestones

Featured News & Press Releases

May 23, 2022: Biohaven provides update on phase 3 clinical trial evaluating troriluzole for spinocerebellar ataxia (SCA)

Nov 08, 2021: Seelos Therapeutics announces FDA acceptance of investigational new drug application and grant of fast track designation for SLS-005 (IV Trehalose) for the treatment of Spinocerebellar Ataxia

Oct 07, 2021: Blade Therapeutics announces publication of preclinical evidence supporting neuroprotective effects of proprietary calpain inhibitor in a rare inherited neurodegenerative disease

Jun 29, 2021: US FDA grants VICO therapeutics orphan-drug designation for VO659, an investigational therapy for spinocerebellar ataxia

Apr 13, 2021: Biohaven announces presentations on troriluzole at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting

Mar 29, 2021: SM Life Sciences submits IND for spinal cerebellar ataxia treatment

Feb 10, 2021: European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an investigational therapy for spinocerebellar ataxia

Dec 21, 2020: Seelos Therapeutics announces issuance of a patent for Trehalose (SLS-005) in Israel

Nov 11, 2020: Biohaven Pharmaceuticals inaugural partner Of National Ataxia Foundation's drug development collaborative

Jan 23, 2020: Cadent Therapeutics announces FDA acceptance of IND application for CAD-1883 for Spinocerebellar Ataxia (SCA)

Jan 22, 2020: Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry

Dec 04, 2019: Seelos Therapeutics receives notice of allowance for an additional US patent for Trehalose (SLS-005)

May 29, 2019: Cadent Therapeutics announces FDA Orphan Drug Designation for CAD-1883 for Spinocerebellar Ataxia

May 07, 2019: Biohaven advances late stage clinical program and novel targets from neuroinnovation platform

May 03, 2019: Biohaven announces presentation of Troriluzole in phase IIb/III trial at American Academy Of Neurology (AAN) 2019 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Spinocerebellar Ataxia (SCA), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Anima Biotech Inc, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Annji Pharmaceutical Co Ltd, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Biogen Inc, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by BioXcel Corp, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Blade Therapeutics Inc, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Celavie Biosciences LLC, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Corestem Inc, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Dystrogen Therapeutics SA, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Enzerna Biosciences LLC, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Everfront Biotech Inc, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Exicure Inc, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Gene Therapy Research Institution Co Ltd, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by IntraBio Ltd, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Ionis Pharmaceuticals Inc, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Locanabio Inc, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Novartis AG, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by PTC Therapeutics Inc, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Q-State Biosciences Inc, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Scnow Biotechnology Co Ltd, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Seelos Therapeutics, Inc., 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Shionogi & Co Ltd, 2022

Spinocerebellar Ataxia (SCA) - Pipeline by Steminent Biotherapeutics Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Triplet Therapeutics Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Vico Therapeutics BV, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Vybion Inc, 2022
Spinocerebellar Ataxia (SCA) - Pipeline by Wave Life Sciences Ltd, 2022
Spinocerebellar Ataxia (SCA) - Dormant Projects, 2022
Spinocerebellar Ataxia (SCA) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Spinocerebellar Ataxia (SCA), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/S21F80D10309EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S21F80D10309EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

